Pharma Mar SA (ES:PHM) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Pharma Mar SA scores a legal victory as the European Commission’s decision to deny marketing authorization for its drug Aplidin is revoked, leading to a dismissal of court proceedings. The company successfully argued a conflict of interest in the original evaluation, and now the European Medicines Agency will re-evaluate the drug for multiple myeloma. The European Commission is ordered to cover its legal costs and those of Pharma Mar.
For further insights into ES:PHM stock, check out TipRanks’ Stock Analysis page.
